Börskollen - Aktier, fonder och ekonominyheter
Börskollen
Tillbakablick: Så här har krisåren format vår syn på ekonomi och samhälle

Pressmeddelanden från Hamlet BioPharma

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts
24 jul 09:00
Hamlet BioPharma
International traction for Hamlet BioPharma17 jul 09:26
Hamlet BioPharma
Uppdatering inför ordinarie teckningsperiod för teckningsoptioner TO5B16 jul 12:13
Hamlet BioPharma
Dialogen med en ledande tysk aktör om partnerskap avseende blåscancerbehandling fortgår i mycket positiv anda29 jun 14:07
Hamlet BioPharma
Hamlet BioPharma Receives European Regulatory Approval for Phase III Study of Alpha1H in Bladder Cancer29 jun 10:35
Hamlet BioPharma
Briefglance Highlights Hamlet BioPharma's Collaboration with the University of Iowa and the Potential for Advanced Bladder Cancer Therapy25 jun 16:00
Hamlet BioPharma
Hamlet BioPharma secures drug manufacturing at Phase III quality and release of Alpha1H for distribution to clinical trial sites23 jun 12:00
Hamlet BioPharma
Hamlet BioPharma’s monthly digital investors’ meeting on June 30th22 jun 17:30
Hamlet BioPharma
Clinical trial expansion in the US, in collaboration with the University of Iowa, to treat high-risk, resistant, non-muscle-invasive bladder cancer (NMIBC)17 jun 11:45
Hamlet BioPharma
Pre-initiation visit in Prague, for the Phase III trial of Alpha1H in bladder cancer10 jun 14:30
Hamlet BioPharma
Continued success for the new anti-infective therapies developed by Hamlet BioPharma08 jun 15:45
Hamlet BioPharma
Utökning av Hamlet BioPharmas kliniska samarbeten med ledande amerikanskt universitet22 maj 09:00
Hamlet BioPharma
Q3 INTERIMREPORTJANUARY–MARCH 202621 maj 11:15
Hamlet BioPharma
Monthly investor meeting on the 22nd of May when Hamlet BioPharma is releasing it’s Q3 report18 maj 15:15
Hamlet BioPharma
Hamlet Biopharma Secures New Patents and Allowances, Going from Strength to Strength in Innovation and Technology23 apr 15:15
Hamlet BioPharma
Monthly investor meeting on the 29th of April30 mar 10:00
Hamlet BioPharma
Hamlet BioPharma presented at the Financial Stockholm event on March 26, 202624 mar 08:46
Hamlet BioPharma
Hamlet BioPharma tillförs cirka 8.5 miljoner kronor genom teckning av teckningsoptioner serie TO5B, s.k. korta optioner17 mar 10:00
Hamlet BioPharma
Hamlet BioPharmas digital monthly investor meeting on the 18th of March15 mar 09:15
Hamlet BioPharma
Styrelsen beslutar om justering av villkoren för teckningsoptioner av serie TO5B och inför ny kompletterande teckningsperiod 16-23 mars 202609 mar 10:45
Hamlet BioPharma
Hamlet BioPharma har undertecknat ett Letter of Intent avseende ett potentiellt kommersiellt avtal avseende Alpha 1H06 mar 18:31
Hamlet BioPharma
Hamlet BioPharma signed a Letter of Intent to outline terms of a potential collaboration and a commercial agreement concerning Alpha 1H.23 feb 10:00
Hamlet BioPharma
Nature Microbiology publicerar banbrytande studie om icke-antibiotisk behandling av återkommande urinvägsinfektioner13 feb 09:00
Hamlet BioPharma
Q2 INTERIM REPORT OCT – DEC 202512 feb 17:03
Hamlet BioPharma
Nature Microbiology publishes the paper ‘’Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.’’11 feb 10:30
Hamlet BioPharma
Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it’s Q2 report03 feb 10:15
Hamlet BioPharma
Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea27 jan 12:00
Hamlet BioPharma
𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿16 jan 14:00
Hamlet BioPharma
Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics18 dec 2025 14:30
Hamlet BioPharma
The HAMLET project featured in Cancerfonden’s Christmas Campaign04 dec 2025 13:00
Hamlet BioPharma
Kommuniké från årsstämma i Hamlet BioPharma AB och efterföljande styrelsemöte14 nov 2025 13:00
Hamlet BioPharma
FDA ger Hamlet BioPharma pivotal status för avgörande Fas III‑studie i blåscancer14 nov 2025 09:00
Hamlet BioPharma
Q1 INTERIM REPORT JULY – SEPT 202513 nov 2025 10:00
Hamlet BioPharma
Hamlet BioPharma bjuder in till digitalt investerarmöte den 14 november 12.0012 nov 2025 10:00
Hamlet BioPharma
Ny styrelsesammansättning stärker Hamlet BioPharma inför kommersialiseringsfas10 nov 2025 09:00
Hamlet BioPharma
Hamlet BioPharma Receives FDA Pivotal-Study Feedback for Novel Neoadjuvant Therapy in Non–Muscle Invasive Bladder Cancer05 nov 2025 14:00
Hamlet BioPharma
Clinical study in infants with febrile kidney infection supports Hamlet BioPharma’s strategy for non-antibiotic treatment of bacterial infections05 nov 2025 14:00
Hamlet BioPharma
Klinisk studie på spädbarn bekräftar Hamlet BioPharmas strategi för icke-antibiotisk behandling av infektioner04 nov 2025 12:30
Hamlet BioPharma
KALLELSE TILL ÅRSSTÄMMA I HAMLET BIOPHARMA AB31 okt 2025 09:00
Hamlet BioPharma
Hamlet BioPharma publicerar årsredovisning 2024/202524 okt 2025 16:10
Hamlet BioPharma
A new approach to treating bacterial infections without antibiotics - targeting the disease response rather than the bacteria24 okt 2025 16:10
Hamlet BioPharma
Clinical studies paving the way for non-antibiotic treatments of bacterial infections; details from the large-scale international study in infants20 okt 2025 09:00
Hamlet BioPharma
Hamlet Biopharma bjuder in till digitalt investerarmöte den 31 oktober 12.0001 okt 2025 09:50
Hamlet BioPharma
Hamlet BioPharma presenterade vid Financial Stockholm-evenemanget den 29 september 202523 sep 2025 09:00
Hamlet BioPharma
Monthly investor meeting on the 25th of September22 sep 2025 13:53
Hamlet BioPharma
Hamlet BioPharma prepares for next steps and secures drug manufacturing of Alpha1H at Phase III quality12 sep 2025 09:44
Hamlet BioPharma
Riktad emission registrerad på Bolagsverket09 sep 2025 12:35
Hamlet BioPharma
Hamlet BioPharma secures new patents to develop scientific discoveries into drugs for the treatment of cancer and infections04 sep 2025 10:38
Hamlet BioPharma
Doctoral thesis to be defended today: Title ‘’Tumor response mechanisms and treatment effects of alpha1-oleate’’28 aug 2025 09:00
Hamlet BioPharma
Year-end Report (Q4) July 2024 – June 202527 aug 2025 14:20
Hamlet BioPharma
Rättelse: Hamlet BioPharma bjuder in till pressträff torsdag 28 augusti27 aug 2025 11:39
Hamlet BioPharma
Hamlet BioPharma bjuder in till pressträff den 28 augusti21 aug 2025 11:15
Hamlet BioPharma
Hamlet BioPharma Announces the Completion of the Alpha1H Phase II Study in Non-Muscle Invasive Bladder Cancer11 aug 2025 12:09
Hamlet BioPharma
Extra bolagsstämma beslutade godkänna styrelsens förslag om riktad nyemission för att finansiera fortsatt utveckling och kommersialisering baserad på tre positiva Fas II studier24 jul 2025 12:36
Hamlet BioPharma
Hamlet BioPharma bjuder in till pressträff den 25 juli24 jul 2025 11:50
Hamlet BioPharma
Kallelse till extra bolagsstämma i Hamlet BioPharma AB (publ)18 jul 2025 14:58
Hamlet BioPharma
Hamlet BioPharma proposes a directed new share issue to finance continued development and commercialization based on three positive Phase II studies18 jul 2025 14:58
Hamlet BioPharma
Hamlet BioPharma föreslår riktad nyemission för att finansiera fortsatt utveckling och kommersialisering baserat på tre positiva Fas II studier25 jun 2025 15:50
Hamlet BioPharma
Hamlet BioPharma Holds Successful In Person Meeting with US FDA17 jun 2025 14:06
Hamlet BioPharma
Hamlet BioPharma announces progress in Tuberculosis therapy17 jun 2025 10:00
Hamlet BioPharma
Hamlet BioPharma invites to investor meeting on the 18th of June22 maj 2025 09:00
Hamlet BioPharma
Q3 INTERIM REPORT JANUARY – MARCH 202521 maj 2025 10:00
Hamlet BioPharma
Hamlet BioPharma bjuder in till pressträff den 22 maj19 maj 2025 13:21
Hamlet BioPharma
Scientific Breakthrough in Alpha1H’s Mechanism of Action19 maj 2025 13:21
Hamlet BioPharma
Vetenskapligt genombrott för Alpha1H:s verkningsmekanism i blåscancer02 maj 2025 11:26
Hamlet BioPharma
Hamlet BioPharma presenterar framgångsrika prekliniska och kliniska data för Alpha1H vid AACR 2025 – stärker positionen inom behandling av blåscancer22 apr 2025 14:38
Hamlet BioPharma
Hamlet BioPharma invites to investor meeting on the 23rd of April08 apr 2025 09:52
Hamlet BioPharma
New scientific advances for Alpha1H highlight the unique discovery pipeline and drug development potential for the treatment of bladder cancer07 apr 2025 16:57
Hamlet BioPharma
New granted patents added to Hamlet BioPharma's extensive patent portfolio in cancer and infection07 apr 2025 16:32
Hamlet BioPharma
Strong Alpha1H treatment effects confirmed in patients with bladder cancer, in final analysis. Clinical study report is being completed for submission to the FDA11 mar 2025 11:58
Hamlet BioPharma
Kommuniké från extra bolagsstämma i Hamlet BioPharma AB (publ) den 11 mars 202521 feb 2025 09:35
Hamlet BioPharma
Hamlet BioPharma bjuder in till investerarmöte den 21 februari20 feb 2025 13:20
Hamlet BioPharma
Kallelse till extra bolagsstämma i Hamlet BioPharma AB (publ)20 feb 2025 13:11
Hamlet BioPharma
Styrelsen för Hamlet BioPharma föreslår ingående av ett licensavtal med Linnane Pharma, vilket skapar förutsättningar för kommersialisering av Bamlet och positiva värden för de båda bolagen20 feb 2025 13:11
Hamlet BioPharma
The board of Hamlet BioPharma proposes licensing agreement with Linnane Pharma, which creates conditions for an effective commercialization of Bamlet and positive value for both companies19 feb 2025 16:00
Hamlet BioPharma
Elisabeth Parker appointed as Business development expert in Hamlet BioPharma and joins the team on March 3rd19 feb 2025 16:00
Hamlet BioPharma
Elisabeth Parker utses till affärsutvecklingsexpert i Hamlet BioPharma och ansluter sig till teamet den 3 mars18 feb 2025 17:07
Hamlet BioPharma
Rättelse: Catharina Svanborg utsedd till Vd och tillträder omgående, styrelseledamot Magnus Nylén tillfällig ordförande18 feb 2025 15:40
Hamlet BioPharma
Catharina Svanborg utsedd till Vd och tillträder omgående, styrelseledamot Magnus Nylén tillfällig ordförande18 feb 2025 15:40
Hamlet BioPharma
Catharina Svanborg appointed as CEO and assumes the position immediately, board member Magnus Nylén acting Chairman13 feb 2025 09:00
Hamlet BioPharma
Q2 Interim Report October 2024 – December 202412 feb 2025 09:35
Hamlet BioPharma
Hamlet BioPharma bjuder in till pressträff den 13 februari med anledning av Q2 rapport03 feb 2025 10:35
Hamlet BioPharma
Presentation den 6.2.25 på Vetenskapsrådets konferens kring Antibiotikaresistens10 jan 2025 15:54
Hamlet BioPharma
Invitation to monthly digital events and presentations of quarterly report10 dec 2024 12:09
Hamlet BioPharma
Hamlet BioPharma presenterar vid Financial Stockholm-evenemanget den 11 december 202403 dec 2024 21:30
Hamlet BioPharma
Hamlet BioPharmas styrelse har idag beslutat om en riktad nyemission av B-aktier om drygt 26 miljoner kronor28 nov 2024 13:25
Hamlet BioPharma
Hamlet BioPharma Participates in Økonomisk Ugebrev’s Life Science Investor Konference 202421 nov 2024 17:11
Hamlet BioPharma
Kommuniké från årsstämma i Hamlet BioPharma AB19 nov 2024 16:49
Hamlet BioPharma
Hamlet BioPharma Participates in the BioStock Life Science Summit 202415 nov 2024 09:00
Hamlet BioPharma
Q1 Interim Report July 2024 – September 202414 nov 2024 13:30
Hamlet BioPharma
Hamlet BioPharma bjuder in till pressträff den 18 november04 nov 2024 11:00
Hamlet BioPharma
Hamlet BioPharma will present at the BioStock Life Science Summit, November 2004 nov 2024 11:00
Hamlet BioPharma
Hamlet BioPharma presenterar på BioStock Life Science Summit 20 november04 nov 2024 10:33
Hamlet BioPharma
Two in-depth features about Hamlet BioPharma in the prestigious CEO world magazines and pulse 2.0 business news website31 okt 2024 11:19
Hamlet BioPharma
Rättelse: Hamlet BioPharma AB publicerar årsredovisning 2023/202431 okt 2024 09:00
Hamlet BioPharma
Hamlet BioPharma publicerar årsredovisning 2023/202424 okt 2024 09:30
Hamlet BioPharma
Kallelse till årsstämma i Hamlet BioPharma AB08 okt 2024 11:06
Hamlet BioPharma
Immunterapi som behandling av återkommande urinvägsinfektioner – nu tre framgångsrika Fas II studier i Hamlet BioPharm01 okt 2024 16:42
Hamlet BioPharma
Hamlet BioPharmas digitala investerarmöte tidigareläggs till den 9 oktober kl. 12:00 CET26 sep 2024 12:08
Hamlet BioPharma
Positive Phase II study shows similar clinical outcomes of immunotherapy and antibiotic treatment for recurrent acute cystitis, potentially reducing the need for antibiotics17 sep 2024 13:48
Hamlet BioPharma
Hamlet BioPharma bjuder in till digitalt investerarmöte den 18 september kl. 12:00